Cell line · CVCL_8794
Papers18
1 to 18 of 18
Download this page as JSON| Paper | Journal | Year | How we know | Retracted | Source |
|---|---|---|---|---|---|
| Development of humanized mouse models for the preclinical evaluation of NK cell-based therapies. | Front Immunol | 2026 | Its Methods give the RRID and name the line | PubMed | |
| CD47 promotes myeloma cell growth through JAK-STAT3/MYC signalling and is targetable by ruxolitinib. | Br J Haematol | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Targeting BCMA in multiple myeloma with a trifunctional NK cell engager. | Cell Rep Med | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Self-Assembling Multi-Antigen T Cell Hybridizers for Precision Immunotherapy of Multiple Myeloma. | Adv Healthc Mater | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Inhibition of acyl-CoA synthetase long-chain isozymes decreases multiple myeloma cell proliferation and causes mitochondrial dysfunction. | Mol Oncol | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Kinetics of Nirogacestat-Mediated Increases in B-cell Maturation Antigen on Plasma Cells Inform Therapeutic Combinations in Multiple Myeloma. | Cancer Res Commun | 2024 | Its Methods give the RRID and name the line | PubMed | |
| Preclinical Evaluation of STI-8811, a Novel Antibody-Drug Conjugate Targeting BCMA for the Treatment of Multiple Myeloma. | Cancer Res Commun | 2024 | Its Methods give the RRID and name the line | PubMed | |
| Multiple mechanisms contribute to acquired TRAIL resistance in multiple myeloma. | Cancer Cell Int | 2024 | Its Methods give the RRID and name the line | PubMed | |
| CRIP1 involves the pathogenesis of multiple myeloma via dual-regulation of proteasome and autophagy. | EBioMedicine | 2024 | Its Methods give the RRID and name the line | PubMed | |
| Systems-level analyses of protein-protein interaction network dysfunctions via epichaperomics identify cancer-specific mechanisms of stress adaptation. | Nat Commun | 2023 | Its Methods give the RRID and name the line | PubMed | |
| miR-17-3p promotes the proliferation of multiple myeloma cells by downregulating P21 expression through LMLN inhibition. | Int J Cancer | 2021 | Its Methods give the RRID and name the line | PubMed | |
| Oxidatively modified low-density lipoproteins are potential mediators of proteasome inhibitor resistance in multiple myeloma. | Int J Cancer | 2021 | Its Methods give the RRID and name the line | PubMed | |
| Physical and Functional Analysis of the Putative Rpn13 Inhibitor RA190. | Cell Chem Biol | 2020 | Its Methods give the RRID and name the line | PubMed | |
| Evaluating the efficacy of multiple myeloma cell lines as models for patient tumors via transcriptomic correlation analysis. | Leukemia | 2020 | Cellosaurus cites it | PubMed | |
| Characterization of Human Cancer Cell Lines by Reverse-phase Protein Arrays. | Cancer Cell | 2017 | Cellosaurus cites it | PubMed | |
| Targeted capture and sequencing of immunoglobulin rearrangements in multiple myeloma to enable detection of minimal residual disease. | 2017 | Cellosaurus cites it | Cellosaurus | ||
| Promiscuous mutations activate the noncanonical NF-kappaB pathway in multiple myeloma. | Cancer Cell | 2007 | Cellosaurus cites it | PubMed | |
| Characterization of the MM.1 human multiple myeloma (MM) cell lines: a model system to elucidate the characteristics, behavior, and signaling of steroid-sensitive and -resistant MM cells. | Exp Hematol | 2003 | Cellosaurus cites it | PubMed |
cell-lines-2026-11-14-0.1.0
Sources 4
- CellosaurusCC BY 4.0, with credit to Cellosaurus (SIB)
- PubMed Central's articlesTitles shown only for CC0, CC BY and public domain articles
- NLM's PMC Article DatasetsCourtesy of NLM, which does not endorse this database
- PubMedNLM's terms
Each source's terms
- CellosaurusCC BY 4.0. Cellosaurus's README: "we have chosen to apply the Creative Commons Attribution 4.0 International (CC BY 4.0) license to Cellosaurus (https://creativecommons.org/licenses/by/4.0/). This means that you are free to copy and redistribute Cellosaurus in any medium or format. You can remix, transform, and build upon Cellosaurus for any purpose, even commercially. You must give appropriate credit, provide a link to the license, and indicate if changes were made." Copyright (c) CALIPHO group, SIB Swiss Institute of Bioinformatics. Read on 14 Nov 2026 at https://ftp.expasy.org/databases/cellosaurus/README
- PubMed Central's articlesEach article's own license. Its words show only under CC0, CC BY or public domain
- NLM's PMC Article DatasetsNLM's PMC Article Datasets on AWS, https://registry.opendata.aws/ncbi-pmc. Its terms: users "acknowledge NLM as the source of the data in a clear and conspicuous manner", do not use the PubMed Central wordmark or the PMC logo, do not "indicate or imply that NLM/NIH/HHS has endorsed" a product, and "only distribute data that are licensed for redistribution". Each article keeps its own license: https://pmc.ncbi.nlm.nih.gov/about/copyright/
- PubMedNLM's terms
Cellosaurus, SIB Swiss Institute of Bioinformatics, https://www.cellosaurus.org, CC BY 4.0. Its problem notes are given in its own words.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/cell-lines/v1/CVCL_8794/papers